This symposium took place on 15th June 2017, as part of the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology 2017 in Madrid, Spain
Chairpersons: Fernando Perez-Ruiz,1 Thomas Bardin,2 Alexander So3
Speakers: Till Uhlig,4 Thomas Bardin,2 Pascal Richette,2 Alexander So,3 Fernando Perez-Ruiz1
1. Basque Country University, Baracaldo, Spain
2. Lariboisière Hospital, Paris, France
3. Centre Hospitalier Universitaire Vaudois, Vaud, Switzerland
4. Diakonhjemmet Hospital, Oslo, Norway
Disclosure: Prof Perez-Ruiz has worked on educational activities with Menarini, Grünenthal, and the Spanish Society for Rheumatology; he is an advisor for AstraZeneca, Grünenthal, and Menarini; and a speaker for Algorithm, Astellas, AstraZeneca, Grünenthal, Menarini, and the Spanish Society for Rheumatology. Prof Perez-Ruiz has received investigatory grants from Biocruces Health Research Institute, Cruces Rheumatology Association, and the Spanish Foundation for Rheumatology. Prof Uhlig has been a consultant for, or has received speakers’ honoraria from, AbbVie, Biogen, Bristol-Myers Squibb, Grünenthal, AstraZeneca, Novartis, Pfizer, Roche, and UCB. Prof Bardin has received research grants from AstraZeneca, Ipsen, and Menarini, with consultancy and/or talks provided to Astellas, AstraZeneca, Biomex, Günenthal, Ipsen, Menarini, Novartis, Savient, and Sobi. Prof Richette has worked with AstraZeneca, Grünenthal, Ipsen, Menarini, and Savient. Prof So is a consultant and advisory board member for Grünenthal, SOBI, and Menarini.
Acknowledgements: Writing assistance was provided by Karolina Windloch, ApotheCom, London, UK.
Support: The publication of this article was funded by Grünenthal. The views and opinions expressed are those of the authors and not necessarily Grünenthal.
Citation: EMJ Rheumatol. 2017;5(Suppl 12):2-10.
Prof Fernando Perez-Ruiz opened the symposium, which focussed on the current unmet need in controlling gout and associated comorbidities with current standard of care. Prof Till Uhlig reviewed the epidemiology and pathogenesis of the disease and Prof Thomas Bardin discussed the burden of gout and its comorbidities. Prof Pascal Richette examined the European League Against Rheumatism (EULAR) treatment guidelines and best clinical practices in treating the disease. Prof Alexander So expanded on why current treatment strategies for gout are not reaching satisfactory disease outcomes. Prof Perez-Ruiz and Prof Bardin focussed on dual therapy with new-in-class uricosuric lesinurad, explaining its mode of action and the associated clinical studies, respectively.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.